Objective To investigate the clinical efifcacy of estradiol on perimenopausal syndrome,and evaluate its safety. Methods 64 cases with perimenopausal syndrome collected in our hospital from January 2010 to January 2011 were used as observation group, and treated with Estradiol valerate. Another 64 cases during the same period were used as control group, and treated with conventional therapy. After treatment, the symptom improvement of both groups were evaluated by the scoring criteria of HAMD and Kupperman, and the related hormone levels were detected and recorded. Adverse reactions after treatment were also observed. Results Clinical results showed that the HAMD and Kupperman score of both groups in end of treatment were better than before treatment, and the improvement degree in observation group were better than control in. The differences were signiifcant (P<0.05). Test results showed that the improvement of various hormonal indicators in observation group were also better than that in control group, the diffierences were significant (P<0.05). 8 cases of adverse reactions were observed in observation group after treatment, 12 cases in control group. Adverse reactions included breast tenderness, vaginal bleeding and gastrointestinal discomfort. The side effects between both groups had no signiifcant difference. Conclusion The efifcacy of Estradiol on perimenopausal syndrome was obvious, it can improve the menopausal symptoms, with less adverse reactions, and improve the life quality of perimenopausal women.

Objective: To investigate anemia rate and to analyze related factors in maternal women in Taicang of Jiangsu province. Methods: There were 13 278 pregnant women who had prenatal care and gave birth in 25 hospitals during 2014-2016 in Taicang of Jiangsu Province. We excluded 1 179 women who registered after 12 weeks of gestation, 144 women who did not test hemoglobin during gestation, and 25 women whose gestational weeks were incorrect. Finally, data from 11 930 pregnant women were analyzed. From the electronical medical record system of maternal and child health care, we obtained basic information of these pregnant women, their hemoglobin levels and related data during gestation and postpartum. Anemia rate was descripted, and factors associated with anemia were identified using multiple unconditional logistic regression. Results: Age of the 11 930 pregnant women was (27.0±4.5) years old, and the P₅₀ (P₂₅-P₇₅) of BMI at the first trimester was 21.4 (19.6-23.7) kg/m². The anemia rate during gestation was 37.2% (4 434/11 930). The anemia rate was 5.5% (276/5 035), 24.4% (1 802/7 377), and 47.8% (3 328/6 966) at the first, second and third trimesters, respectively. Anemia rate at 42 days postpartum was 19.9% (680/3 418). Multiple unconditional logistic regression indicated that anemia during gestation was related with maternal age <21 years old at prenatal registration (OR (95%CI): 1.28 (1.07-1.53)), body mass index(BMI) <18.5 kg/m² at the first trimester (OR (95%CI): 1.14 (1.00-1.29)), non-local residence (OR (95%CI): 1.35 (1.20-1.52)), education of middle school and lower (OR (95%CI): middle school: 1.24 (1.05-1.47), primary school: 1.36 (1.01-1.82)), occupation of housewife or farmer (OR (95%CI): housewife: 1.21 (1.06-1.38), farmer: 1.21 (1.03-1.44)). Anemia at 42 days postpartum was associated with multipara (OR(95%CI): 1.59 (1.12-2.27)), anemia at the first trimester (OR(95%CI): 3.26 (1.92-5.55)), no folic acid supplementation at the first trimester (OR(95%CI): 1.34 (1.00-1.80)), and hemorrhage≥500 ml during 24 h postpartum (OR(95%CI): 2.26 (1.02-4.97)). Conclusion Anemia rate was low for maternal women in Taicang of Jiangsu Province. The factors associated with gestational anemia included pregnant women's age, BMI, local or non-local residence, occupation, and education. The factors associated with postpartum anemia included multipara, anemia at the first trimester, no folic acid supplementation at the first trimester, and hemorrhage 24 h postpartum.